We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Pathway Leads to Pancreatic Cancer

By LabMedica International staff writers
Posted on 25 Feb 2013
Cancer researchers have outlined the molecular pathway that regulates the transformation of normal pancreatic tissue into pancreatic ductal adenocarcinoma cells.

Investigators at the University of Pennsylvania (Philadelphia, USA) profiled gene expression in mouse pancreatic tissues from several different biological states: during embryonic development, acute pancreatitis, and K-ras mutation-driven carcinogenesis. More...
Of particular interest were changes that occurred in exocrine cells during acinar-ductal metaplasia (ADM), an inflammatory state that is a prelude to the development of pancreatic ductal adenocarcinoma.

They reported in the February 2013 issue of the journal Genes and Development that the protein Prrx1 (paired related homeobox 1) was a key element in the pathway leading to transformation into cancer. Prxx1 is a DNA-associated protein that is a member of the paired family of homeobox proteins localized to the nucleus. The protein functions as a transcription coactivator, enhancing the DNA-binding activity of serum response factor, a protein required for the induction of genes by growth and differentiation factors.

Results of the current study revealed that Prxx1was present in two isoforms, Prrx1a and Prrx1b. Prxx1a was shown to regulate migration while Prxx1b regulated invasion in pancreatic cancer cells and was enriched in circulating pancreatic cells. Additionally, the Prrx1b isoform, which was also induced in ADM, bound the Sox9 promoter and positively regulated Sox9 expression. This finding suggested a new hierarchical scheme whereby a Prrx1–Sox9 axis may influence the emergence of ADM and regeneration.

“We hope that studies like this one that identifies key molecules and pathways that govern the cancerous fate of cells can be used as diagnostic predictors of treatment outcome and severity for cancer,” said senior author Dr. Anil Rustgi, professor of gastroenterology at the University of Pennsylvania.

Related Links:
University of Pennsylvania


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.